Skip to main content
. 2018 Jan 10;84(3):510–519. doi: 10.1111/bcp.13467

Table 1.

Noncompartmental pharmacokinetic analysis of probes

Drug Parameter Without dicloxacillin With dicloxacillin GMR (95% CI)
Tolbutamide
(CYP2C9)
AUC0–24 h (ng*h ml–1) 621 507 (505775–744 162) 404 391 (355015–582 480) 0.73 (0.65, 0.81)
Cmax (ng ml–1) 51 706 (48907–54 467) 49 130 (47739–52 615) 0.93 (0.87, 1.00)
T½ (h) 9.0 (6.8–13.5) 6.1 (4.8–9.2) 0.72 (0.65, 0.79)
CLf (l h–1) 0.06 (0.05–0.12) 0.12 (0.09–0.16) 1.64 (1.44, 1.87)
Omeprazole
(CYP2C19)
AUC0–24 h (ng*h ml–1) 228.4 (188.8–343.7) 80.2 (63.7–101.1) 0.33 (0.24, 0.45)
Cmax (ng ml–1) 149.5 (105.5–242.2) 58.0 (42.8–77.3) 0.40 (0.25, 0.66)
T½ (h) 1.5 (1.2–3.5) 3.5 (2.2–5.6) 1.62 (0.71, 3.71)
CLf (l h–1) 1.9 (0.5–4.3) 3.7 (1.7–7.5) 2.01 (0.69, 5.89)
Midazolam
(CYP3A4)
AUC0–24 h (ng*h ml–1) 37.4 (31.9–44.0) 23.5 (14.6–29.1) 0.54 (0.41, 0.72)
Cmax (ng ml–1) 12.0 (9.6–13.7) 8.9 (6.2–12.5) 0.77 (0.59, 1.01)
T½ (h) 7.6 (5.5–9.9) 7.7 (6.3–8.5) 1.08 (0.87, 1.33)
CLf (l h–1) 38 (31–43) 67 (42–80) 1.59 (1.23, 2.06)
Dextromethorphan
(CYP2D6)
AUC0–24 h (ng*h ml–1) 12.0 (5.4–24.5) 4.5 (2.7–11.2) 0.52 (0.32, 0.83)
Cmax (ng ml–1) 1.15 (0.74–2.5) 0.76 (0.65–0.95) 0.69 (0.54, 0.89)
T½ (h) (n = 6) 13.9 (12.4–18.2) 21.4 (11.8–25.1) 1.25 (0.53, 2.93)
CLf (l h–1) 771 (275–1927) 1561 (483–2800) 1.57 (0.97, 2.55)
Caffeine a
(CYP1A2)
AUC0–24 h (ng*h ml–1) 22 447 (20671–27 837) 19 358 (14563–23 851) 0.81 (0.71, 0.92)
Cmax (ng m–1l) 3185 (2936–3890) 3213 (2838–3422) 0.92 (0.81, 1.04)
T½ (h) 4.5 (3.9–4.6) 4.0 (3.0–4.8) 0.88 (0.79, 0.99)
CLf (1 h–1) 0.45 (0.33–0.50) 0.47 (0.38–0.62) 1.17 (0.98, 1.39)

Data are shown as medians with interquartile ranges. AUC0–24 h, area under the plasma concentration–time curve from 0 to 24 h; CI, confidence interval; Cmax, maximum plasma concentration; CLf: formation clearance of the main metabolite; CYP, cytochrome P450; GMR, geometric mean ratio; T½, half‐life

a

Pharmacokinetic data for only 10 individuals for caffeine are shown